Response Genetics, Inc. to Offer FDA-Approved Anaplastic Lymphoma Kinase (ALK) Test for Metastatic NSCLC

Approximately 3 to 5 percent of NSCLC tumors have a rearrangement of the ALK gene, which can lead to impaired programmed cell death and abnormal cell growth. Using the new ALK Break Apart FISH Probe Kit, Response Genetics can detect rearrangements of the ALK gene on the 2p23 chromosome in tumors. The ALK Break Apart FISH Probe Kit is the only available diagnostic assay clinically validated to predict response to the targeted therapy XALKORI®.

“Diagnostics are playing an increasingly important role in cancer care by providing physicians with the information they need to determine the safest and most effective treatment for each patient,” said Denise McNairn, Interim CEO of Response Genetics. “Through the development of our leading edge ResponseDX™ genetic test panels, we have a proven track record in advancing patient care. And now, with the addition of FISH-based ALK testing capabilities, we are even better positioned to provide valuable clinical information, thus helping reduce the impact of diseases such as NSCLC on patients’ lives.”